Treatment of Vascular Anomalies With Sirolimus: An Updated Comprehensive Review
DOI:
https://doi.org/10.48729/pjctvs.614Keywords:
sirolimus, vascular anomalies, imunosupressive agents/adverse effects, vascular malformations, quality of lifeAbstract
Background: Sirolimus, an mTOR inhibitor, has transformed the management of complex slow- flow vascular malformations (VAMs), particularly those driven by PI3K/AKT/mTOR pathway activation. Evidence from prospective trials and real- world cohorts supports its use in venous, lymphatic and combined malformations, as well as in PIK3CA- related overgrowth spectrum (PROS) and PTEN hamartoma tumor syndrome (PHTS). However, sirolimus shows poor or absent benefit in fast- flow lesions such as arteriovenous malformations (AVMs).
Methods: This narrative review of the recent literature (2020- 2025) was performed using PubMed, focusing on molecular mechanisms, clinical efficacy, safety, quality of life, therapeutic drug monitoring (TDM) and cost- utility of sirolimus in vascular anomalies.
Results: Sirolimus demonstrates high response rates in slow- flow malformations, with partial responses in approximately 60−85%60−85% of patients and clinically meaningful improvements in health- related quality of life (HRQoL). Lower trough levels (4- 10 ng/mL) provide comparable efficacy with reduced toxicity. Adverse effects include oral mucositis, dyslipidemia, fatigue and infections. In contrast, fast- flow malformations show negligible benefit, consistent with their distinct genetic architecture, which predominantly activates RAS/MAPK rather than PI3K/AKT/mTOR signalling.
Conclusions: Sirolimus is an effective targeted therapy for refractory slow- flow vascular malformations but should not be considered a universal treatment for all vascular anomalies. Future directions include molecularly guided therapy, rational combination regimens and integration with PI3K- and AKT- directed agents.
Downloads
References
Goldenberg DC, Vikkula M, Penington A, Blei F, Kool LS, Wassef M, et al. Updated Classification of Vascular Anomalies. A living document from the International Society for the Study of Vascular Anomalies Classification Group. J Vasc Anom (Phila). 2025;6(2).
Soblet J, Limaye N, Uebelhoer M, Boon LM, Vikkula M. Variable Somatic TIE2 Mutations in Half of Sporadic Venous Malformations. Mol Syndromol. 2013;4(4):179-83.
Stor MLE, Horbach SER, Lokhorst MM, Tan E, Maas SM, van Noesel CIM, et al. Genetic mutations and phenotype characteristics in peripheral vascular malformations: A systematic review. J Eur Acad Dermatol Venereol. 2024;38(7):1314-28.
Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606-19.
Eng C. PTEN: one gene, many syndromes. Hum Mutat. 2003;22(3):183-98.
Freixo C, Ferreira V, Martins J, Almeida R, Caldeira D, Rosa M, et al. Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review. Journal of Vascular Surgery. 2020;71(1):318-27.
Shimano KA, Eng W, Adams DM. How we approach the use of sirolimus and new agents: Medical therapy to treat vascular anomalies. Pediatric Blood & Cancer. 2022;69(53):e29603.
Ji Y, Chen S, Zhou J, Yang K, Zhang X, Xiang B, et al. Sirolimus plus prednisolone vs sirolimus monotherapy for kaposiform hemangioendothelioma: a randomized clinical trial. Blood. 2022;139(11):1619-30.
Nguyen HL, Bonadurer GF, 3rd, Tollefson MM. Vascular Malformations and Health- Related Quality of Life: A Systematic Review and Meta- analysis. JAMA Dermatol. 2018;154(6):661-9.
Harbers VEM, Bouwman FCM, van Rijnsoever IMP, Verhoeven BH, van der Vleuten CJM, Schultze Kool LJ, et al. Magnitude and relevance of change in health- related quality of life in patients with vascular malformations treated with sirolimus. Front Med (Lausanne). 2023;10:1155476.
Akita S, Houbara S, Hirano A. Management of Vascular Malformations. Plastic and Reconstructive Surgery - Global Open. 2014;2(3):e128.
Horbach SER, van de Ven JS, Nieuwkerk PT, Spuls PI, van der Horst CMAM, Reekers JA. Patient- Reported Outcomes of Bleomycin Sclerotherapy for Low- Flow Vascular Malformations and Predictors of Improvement. Cardiovasc Intervent Radiol. 2018;41(10):1494-504.
Neirotti A, Barat V, Coppo P, La Selva R, Manicone R, Cotti R, et al. Therapy with sirolimus in vascular anomalies: the experience of two Italian centers on 14 pediatric patients. Front Pediatr. 2024;12:1434493.
Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274-93.
Lee D-F, Hung M-C. All Roads Lead to mTOR: Integrating Inflammation and Tumor Angiogenesis. Cell Cycle. 2007;6(24):3011-4.
Harbers VEM, Zwerink LGJM, Rongen GA, Klein WM, van der Vleuten CJM, van Rijnsoever IMP, et al. Clinical differences in sirolimus treatment with low target levels between children and adults with vascular malformations - A nationwide trial. Clinical and Translational Science. 2023;16(5):781-96.
Seront E, Van Damme A, Legrand C, Bisdorff-Bresson A, Orcel P, Funck-Brentano T, et al. Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations. JCI Insight. 2023;8(21).
Wang G, Lu W, Zhu Y, Wang C, Yang X. Effectiveness and safety of sirolimus in the treatment of venous malformations: A meta-analysis of prospective studies. J Vasc Surg Venous Lymphat Disord. 2025;13(6):102284.
Teng J, Martini J, Kelly M, Tollefson M, Greer A. Sirolimus for Venous Malformations: A Systematic Review of Efficacy and Safety. Lymphatic Research and Biology. 2025;23(6):311-9.
Kim M, Hong KT, Park HJ, Kim BK, Choi JY, Kim HY, et al. Clinical effectiveness and safety of sirolimus in pediatric patients with complex vascular anomalies: necessitating personalized and comprehensive approaches. Front Pediatr. 2023;11:1304133.
Fernández Oliveira C, Martínez Roca C, Gómez Tellado M, Salvador Garrido MP, Outeda Macías M, Martín Herranz I. Treatment with oral or topical sirolimus in complex vascular anomalies in pediatrics. Experience in a third-level hospital. Cir Pediatr. 2023;36(2):60-6.
Zabeida A, Brzezinski JJ, Wasserman JD, Cytrynbaum C, Weksberg R, Zwicker K, et al. Sirolimus for vascular anomalies associated with PTEN hamartoma tumor syndrome. Pediatr Blood Cancer. 2024;71(11):e31282.
Zhang Z, Li Y, Zhang G, Yang K, Qiu T, Zhou J, et al. Safety Evaluation of Oral Sirolimus in the Treatment of Childhood Diseases: A Systematic Review.
Navarro M, Allemang-Trivalle A, Leducq S, Jonville-Bera A-P, Maurier A, Zejli T, et al. Indication for a Pneumocystis Prophylaxis Therapy in Patients with Vascular Anomalies Treated with PIK3/AKT/mTOR Pathway Inhibitors: Experts' Opinion and Systematic Review from the Literature. Dermatology. 2024;239(6):942-51.
Qiu T, Li Y, Gong X, Zhou J, Yang K, Zhang X, et al. Oral antibiotic prophylaxis for infection in patients with vascular anomalies receiving sirolimus treatment: a multicenter retrospective study. Orphanet J Rare Dis. 2023;18(1):121.
Ho YH, Zhao YT, Guo HL, Li Y, Zhang YY, Wang J, et al. Therapeutic Drug Monitoring for Sirolimus in Children with Vascular Anomalies: What Can We Learn from a Retrospective Study. Pharmaceuticals (Basel). 2024;17(10).
Li GX, Sebaratnam DF. Cost-utility of sirolimus in the treatment of vascular malformations. Australas J Dermatol. 2024;65(8):e259-62.
Kane G, Fernandez-Pineda I. Targeted therapies for vascular malformations. Front Med (Lausanne). 2024;11:1446046.
Restrepo-Espinosa V, Lee AI, Prozora S, Patel P, Nassiri N. In-human clinical experience with direct stick embolization of low-flow vascular malformations using a mammalian target of rapamycin inhibitor. J Vasc Surg Venous Lymphat Disord. 2025;13(2):101997.
Downloads
Published
How to Cite
License
Copyright (c) 2026 Portuguese Journal of Cardiac Thoracic and Vascular Surgery
This work is licensed under a Creative Commons Attribution 4.0 International License.
